Metal-free and light-promoted radical iodotrifluoromethylation of alkenes with Togni reagent as the source of CF<sub>3</sub> and iodine
作者:Redouane Beniazza、Maxime Douarre、Dominique Lastécouères、Jean-Marc Vincent
DOI:10.1039/c7cc00214a
日期:——
Iodotrifluoromethylation of alkenes is effectively conducted by combining benzophenone, “black light”, isopropanol and Togni reagent 1 as the source of both the CF3 group and iodine atom.
[EN] UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS D'ISOXAZOLE CONTENANT DE L'URÉE UTILISÉS COMME AGONISTES DE FXR ET LEURS PROCÉDÉS D'UTILISATION
申请人:ENANTA PHARM INC
公开号:WO2018081285A1
公开(公告)日:2018-05-03
The present invention provides compounds of Formula (I), Pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR- mediated or TGR5-mediated diseases or conditions.
[EN] ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF<br/>[FR] ANALOGUES DE L'ISOXAZOLE EN TANT QU'AGONISTES DE FXR ET LEURS PROCÉDÉS D'UTILISATION
申请人:ENANTA PHARM INC
公开号:WO2018067704A1
公开(公告)日:2018-04-12
The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
[EN] ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF<br/>[FR] ANALOGUES DE L'ISOXAZOLE UTILISÉS EN TANT QU'AGONISTES DE FXR ET LEURS PROCÉDÉS D'UTILISATION
申请人:ENANTA PHARM INC
公开号:WO2019118571A1
公开(公告)日:2019-06-20
The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.